Search Results - Alan Menter

Summary of Research: Switching Between Adalimumab Reference Product and BI 695501 in Patients with Chronic Plaque Psoriasis (VOLTAIRE-X): A Randomized Controlled Trial by Alan Menter

Connect to this object online.

A Summary of 2018 and What Lies Ahead for Dermatology and Therapy in 2019 by Alan Menter, Richard Warren

Connect to this object online.

The Validity of Cutaneous Body Image as a Construct and as a Mediator of the Relationship Between Cutaneous Disease and Mental Health by Sarah B. Hinkley, Shayla C. Holub, Alan Menter

Connect to this object online.

Calcipotriol/Betamethasone Dipropionate Cutaneous Foam Treatment for Psoriasis in Patients With BSA 5-15% and PGA ≥ 3: Post-Hoc Analysis From Three Randomized Controlled Trials... by Lars Iversen, Merle Kurvits, Anja Marieke Snel-Prentø, Alan Menter

Connect to this object online.

Brodalumab to the Rescue: Efficacy and Safety of Brodalumab in Patients with Psoriasis and Prior Exposure or Inadequate Response to Biologics by Alan Menter, April Armstrong, Abby Van Voorhees, Clive Liu, Abby Jacobson

Connect to this object online.

IL-23 Inhibitors for Moderate-to-Severe Plaque Psoriasis: A Review of Clinical Efficacy, Safety, and Tolerability by Sima D. Amin, Annika S. Silfvast-Kaiser, So Yeon Paek, Dario Kivelevitch, Alan Menter

Connect to this object online.

Treatment of Psoriasis with Secukinumab in Challenging Patient Scenarios: A Review of the Available Evidence by Jashin J. Wu, Joseph F. Merola, Steven R. Feldman, Alan Menter, Mark Lebwohl

Connect to this object online.

Correction to: Treatment of Psoriasis with Secukinumab in Challenging Patient Scenarios: A Review of the Available Evidence by Jashin J. Wu, Joseph F. Merola, Steven R. Feldman, Alan Menter, Mark Lebwohl

Connect to this object online.

A Real-World Evaluation of the Long-Term Safety and Efficacy of Infliximab in the Treatment Moderate-to-Severe Psoriasis by Emily K. Haque, Aaminah Azhar, John Corbett, Jillian Frieder, Xuan Wang, Alan Menter

Connect to this object online.

Injection Site Reactions in the Federal Adverse Event Reporting System (FAERS) Post-Marketing Database Vary Among Biologics Approved to Treat Moderate-To-Severe Psoriasis by Elsie Grace, Orin Goldblum, Lisa Renda, Noah Agada, Kyoungah See, Craig Leonardi, Alan Menter

Connect to this object online.

Topical dermal steroid-induced retinopathy by Taylor Hilton, MS, Andrew DeCrescenzo, MD, Alan Menter, MD, Sai H. Chavala, MD

Connect to this object online.

Use of tumor necrosis factor alpha (TNF α) antagonists in a patient with psoriasis and Chagas disease by Cristián Navarrete-Dechent, Daniela Majerson, Marisa Torres, Daniela Armijo, Mahir Patel, Alan Menter, Claudia de la Cruz

Connect to this object online.